Semaglutide reduces cardiovascular events in patients with atherosclerotic disease and obesity
1. Patients assigned to semaglutide reported reduced major adverse cardiovascular events, regardless of heart failure subtype. 2. Benefits were consistent across baseline characteristics such as age, BMI, and diuretic use. Evidence Rating Level: 1 (Excellent) Study...